AI adoption in life science labs faces a growing skills barrier
Pistoia Alliance survey also found that the greatest benefit for lab digitalisation has shifted from efficiency to innovation.
List view / Grid view
Pistoia Alliance survey also found that the greatest benefit for lab digitalisation has shifted from efficiency to innovation.
Jianbo Diao, PhD, Director of Bioanalytical Services, WuXi AppTec, discusses the importance for mRNA therapy developers of adopting precise and flexible analytical strategies for future pipeline success.
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
In this App Note, MBV AG showcases the MAS-100 Sirius as the advanced successor to the MAS-100 NT, offering significantly enhanced capabilities for quantitative monitoring of airborne viable particles in cleanrooms.
Bioprocess experts from Sartorius BIA Separations and BridgeBio Gene Therapy illustrate an approach with potential to expedite AAV upstream analytics and lower overall process development costs.
This in-depth focus features articles on rapid microbiological methods, quality control, and using AI to read agar plates.
This in-depth focus features articles on cell and gene therapy in Europe and enhancing drug delivery with cost-effective solutions.
In this Guide to Outsourcing article, Doug Botkin, PhD Scientific Portfolio Specialist from Charles River Laboratories, examines how modern microbial ID tools can enhance contamination control strategies and explores the benefits an outsourcing partner can provide.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
The medicine becomes the first EU-approved oral treatment for adults who have postpartum depression (PPD).
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
Expanding its collaboration with the US biotech will add novel molecular glue degrader-based medicines to the pharma company’s pipeline.
The novel approach could enhance quality testing applications in pharmaceutical manufacturing.
Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.